-
2023-505277-32-00
5
2023-01-26
Diffuse Large B-Cell Lymphoma (DLBCL)
-
2022-500391-62-00
9
2023-01-19
Subjects with relapsed/refractory peripheral T-cell lymphoma (R/R PTCL
-
2024-511267-28-00
5
2021-02-17
B-cell malignancies
-
2022-501687-18-00
4
2020-10-28
Advanced malignancies and IAI diseases
-
2023-510509-17-00
7
2020-06-17
Relapsed and/or refractory Acute Myeloid Leukemia
-
2025-522632-14-00
4
2026-05-11
Non-small cell lung cancer (NSCLC)
-
2024-519369-24-00
5
2026-01-29
METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER
-
2025-521441-24-00
7
2026-01-19
Advanced or Metastatic Solid Tumors
-
2024-519798-20-00
4
2026-01-15
pMMR/MSS or MSI-Low Locally Advanced Rectal Cancer (LARC)
-
2025-520730-28-00
4
2025-12-08
Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung
-
2025-521281-97-00
5
2025-12-02
Non-Small Cell Lung Cancer (NSCLC)
-
2025-521511-40-00
10
2025-11-18
metastatic non-small cell lung cancer
-
2024-517553-26-00
5
2025-11-12
Advanced ALK-positive non-small cell lung cancer (NSCLC)
-
2024-516794-70-00
4
2025-11-03
Metastatic non-squamous non-small cell lung cancer
-
2025-521147-21-00
4
2025-10-08
Lung Cancer
-
2024-517232-22-00
5
2025-09-26
KRAS G12C-mutant, Locally Advanced Unresectable or Metastatic Colorect
-
2024-514030-20-00
4
2025-08-29
colorectal cancer
-
2024-520154-38-00
5
2025-07-29
Acute Myeloid Luekemia
-
2024-515098-93-00
5
2025-07-22
Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML
-
2024-517247-31-00
5
2025-07-07
Newly Diagnosed Higher Risk Myelodysplastic Syndrome
-
2024-513682-40-01
5
2025-07-04
Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer
-
2024-517789-41-00
6
2025-07-04
metastatic or locally advanced renal cell carcinoma
-
2024-518469-84-00
4
2025-06-20
Colorectal cancer
-
2024-513122-27-00
5
2025-06-10
Unresectable, Locally Advanced or Metastatic HER2 positive Gastric or